Drug recall · July 29, 2020
Cefdinir for Oral Suspension USP recall
Why: Superpotent Drug: Out-of-specification (OOS) result observed in an assay test of retention samples.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Cefdinir for Oral Suspension USP, 250 mg/5mL, packaged in 60 mL bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited, Mandideep, India, NDC 68180-723-20
- Lots / codes
Lot # F802189, Exp 10/2020, F900240, Exp 1/2021
- Quantity
- 35,928 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- U.S.A. Nationwide
- Initiated
- July 2, 2020 · Voluntary: Firm initiated
- Classified
- July 23, 2020
- Reported
- July 29, 2020
- Ended
- June 30, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cefdinir
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.